(RTTNews) - Small molecule drug developer Synta Pharmaceuticals Corp. (SNTA: News ) Thursday reported a lower loss for the fourth quarter, helped by a one-time acceleration of deferred revenue related to a former partnership agreement. Lexington ...
... 5.9 Total assets $ 862.0 $ 523.9 LIABILITIES: Current liabilities: Accounts payable $ 10.7 $ 13.9 Accrued expenses, including income taxes payable 68.4 65.9 Deferred revenue - current portion 27.3 24.8 Note payable - current portion ...
At January 31, 2010, the Company had deferred revenue of approximately $200.4 million as compared to approximately $201.5 million at January 31, 2009. The January 31, 2009 deferred revenue, if valued at currency exchange rates as of January 31, 2010 ...
... 270 37,957 Restructuring accruals, current portion 2,026 2,052 Short-term loans 8,265 11,964 Convertible notes 160,961 51,729 Derivatives of convertible notes 41,189 - Deferred revenue 61,977 59,975 Deferred tax liabilities 438 1,828 ...
... unclear whether the correction of the error will result in a restatement to provide further disclosure about the basis for the Company's accounting, or in a restatement of revenue and deferred revenue, as described in more detail below and in ...
Despite reporting a fourth quarter loss, Lexington-based biotech Synta Pharmaceuticals Corp. ended 2009 with a net profit of $79.1 million thanks in large part to deferred revenue through a broken partnership with GlaxoSmithKline. GSK cancelled the ...
|
Instantly
